Latest Breaking News On - மருந்து கண்டுபிடிப்பு முயற்சிகள் - Page 1 : comparemela.com
Emory receives record funding for research with $894 million in last year
emory.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from emory.edu Daily Mail and Mail on Sunday newspapers.
Vaxart Announces Exclusive Worldwide License Agreement with
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Mr. Adams is a journalist in Atlanta who has written about the pharmaceutical industry.
ATLANTA Nine years ago, Dr. Dennis Liotta, a professor of organic chemistry at Emory University, set out to change the way drugs are developed for so-called neglected diseases those that primarily affect populations in poorer countries and for which there exist few, if any, safe and effective treatments.
“The cold hard truth is that it can cost billions of dollars and take decades to develop a new drug,” he said during a TEDx talk in 2016, shortly after the World Health Organization had declared the Zika virus a neglected disease that had long been overlooked in the African countries where it is endemic an international public health emergency. “So pharmaceutical companies almost invariably only pursue drugs for diseases that will generate large profits.”
VIC Technology Venture Development Announces New Additions to Strategic Advisory Board, Bringing Together Industry Veterans to Guide Medical Innovation
Share Article
Dr. Dennis Liotta and Dr. Paul Atkins
“They are both innovative, life science veterans that have taken impactful technologies from the earliest stage to highly successful exits and we are fortunate to have them on our team.” said Calvin Goforth, Chief Executive Officer of VIC. FAYETTEVILLE, Ark. (PRWEB) May 17, 2021 VIC Technology Venture Development, which creates and develops high impact life science companies based on technologies exclusively licensed from top research institutions worldwide, announced today two new distinguished additions to their Strategic Advisory Board from across the life science industry.
by Swarajya Staff - May 3, 2021 08:17 AM
Merck Pharma
Snapshot
Molnupiravir is currently undergoing a phase-3 trial for the treatment of non-hospitalised patients with confirmed Covid-19.
An experimental oral antiviral drug called molnupiravir, manufactured by the American pharmaceutical company, Merck, is expected to help stem the cases of coronavirus in India.
The company, which is also known as MSD outside the United States and Canada, announced earlier last week that it has entered into non-exclusive voluntary licensing agreements for the drug with five established Indian generics manufacturers.
Even though there are two Covid-19 vaccines in IndiaâCovaxin and Covishieldâ it is believed that molnupiravir would play a key role in fighting the massive health crisis in the country.
vimarsana © 2020. All Rights Reserved.